Sophia
  • Our Project
  • Funders
  • Advisors
    • Patient Advisory Board
    • Reimbursement Board
    • Strategic Advisory Board
  • Partners
    • Academic Partners
    • Efpia
    • SMEs
    • Associated Partners
  • Meet the Scientists
    • SOPHIA Aspiring Scientists
    • SOPHIA Young Scientist Award
  • Publications
  • News
  • Search
  • Menu Menu
Metabolon, Inc. MET

Metabolon MET

Metabolon, Inc. is the leader in high-throughput metabolomics technology since 2000. Metabolon operates its metabolomic technology platform in state-of-the-art laboratory facilities, with headquarters located in Durham, NC. Metabolon has advanced the field of metabolomics by pioneering and patenting the industry’s leading high throughput metabolomics platform. With over 90 patents covering processes and metabolomics methods (analytical and informatics), Metabolon has developed the technology to quickly identify and measure most of the metabolites in a biological sample. Our unique informatics systems, refined methods and extensive chemical reference library of more than 5,200 known and 8,000 novel metabolites produce the highest and most precise coverage (to our knowledge and reported in the public domain) of any metabolomics platform. Metabolon also has unique lipidomics capabilities with (to our knowledge) the only complex lipid platform that delivers complete and quantitative coverage of all the major classes of complex lipids.

MET PERSONNEL WORKING ON SOPHIA

Gregory Michelotti

Third-I 3i bvba

Third-I 3i bvba

Third-i bvba is an innovative SME focussing on participatory, quadruple helix policy stakeholder engagement in the transformation of health ecosystems into person driven models. We have expertise in value-based healthcare (and related value-based procurement), multi-stakeholder engagement for establishing policy pathways which can be transformed into sustainable practices. We have hands on experience of Scoping the value of innovation (and link to video) in cancer care in patient centric multi-stakeholder environments.

Third-I PERSONNEL WORKING ON SOPHIA

Jacqueline Bowman-Busato

Atturos ATT

Atturos ATT

Atturos is a young and innovative University College Dublin (UCD) spin-out company (December 2016) focussed on developing advanced multiplexed blood protein biomarker solutions to improve patient outcomes and have a global impact. Atturos’expertise and protein biomarker platform supports the development and implementation of analytically validated multiplexed protein biomarker assays to meet significant unmet clinical needs in chronic diseases. Atturos has a portfolio of in-house and licence-pending protein biomarker tests in development (clinical validation). The value of the platform has been identified by a number of blue-chip pharma companies who are working with Atturos to apply the platform (and assays) to their clinical translational efforts.

ATT PERSONNEL WORKING ON SOPHIA

Stephen Pennington

Lipotype GmbH LIPO

Lipotype GmbH LIPO

Drawing on many years of cutting-edge research experience, Lipotype delivers comprehensive, absolutely quantitative lipid analysis services for clinical and biological samples on a high-throughput scale. Lipotype offers high quality lipid analysis services for a wide range of customers and applications, including biomarker identification for clinical researchers, pharma and biotech companies, functional food development for the food industry, and also for the small-scale profiling needs of academic researchers. Lipotype is GMP certified.

LIPO PERSONNEL WORKING ON SOPHIA

Kai Simons

Christian Klose

Mathias Gerl

MACCABI HEALTH SERVICES KSM

maccabi | Mizra Medical
MACCABI HEALTH SERVICES

Maccabi Research and Innovation Centre (KSM), was founded in 2016. The research centre has a unique access to Maccabi’s professional abilities and wealth of medical knowledge, including a large database of 2.5 million members with 30 years of data collection. Since its establishment Maccabitech – the epidemiological & clinical research arm of Maccabi Healthcare Services at KSM mined MHS’s rich medical, biological, and demographic data on its patient population, collected over decades of providing care. The work has facilitated the publication of over 200 research papers, enabled ten major collaborations, and aided in the development of well over 20 novel products and tools in healthcare practice to improve outcomes for MHS and beyond. The KSM is a major player in data-driven medical research and operates by enabling many researchers to access and work with MHS data and by internally developing research projects and algorithm-based precision medicine tools. Macbbitech’s activities span in four primary, mutually reinforcing domains: epidemiological investigation and
observational studies, Clinical trials, the Biobank and Product development.

MACCABI PERSONNEL WORKING ON SOPHIA

Avraham Karasik

 Gabriel Chodick, PhD

Cheli Melzer – Cohen, MSc

Adi Renert

Imprint   Privacy  Contact   

                     

 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875534. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, and Obesity Action Coalition.

Scroll to top